Use of Thrombopoietin Receptor Agonists in Prolonged Thrombocytopenia after Hematopoietic Stem Cell Transplantation.
Prolonged thrombocytopenia after HSCT is a strong risk factor for transplant related mortality and morbidity, and no standard treatment guideline exists. Thrombopoietin receptor agonists (TPO-RAs), eltrombopag and romiplostim, increases the platelet production, and are being increasingly used in various conditions with thrombocytopenia. In this review, we present an overview of these TPO-RAs and review their efficacy and safety in prolonged post HSCT thrombocytopenia. Through a systematic literature search, we identified 25 reports describing their use for this indication. Thirteen reports (8 case series and 5 case reports) described the use of eltrombopag in 78 patients with Prolonged Isolated Thrombocytopenia (PIT) and 43 patients with Secondary Failure of Platelet Recovery (SFPR). A consistent and durable response with the rise in platelet counts above 50 × 10 9/L for 7 consecutive days without platelet transfusion was seen in 85 out of 121 patients (Overall Response Rate, ORR 70%). Amongst the responders, 56 were patients with PIT (ORR for PIT of 72%) versus 29 patients with SFPR (ORR for SFPR of 67%). No serious grade 3 or 4 adverse effects were reported. Similarly, 12 reports (6 case series and 6 case reports) described the use of romiplostim in prolonged post HSCT thrombocytopenia (17 patients with PIT and 32 patients with SFPR). Response with the increment of platelet count was described in 40 out of 49 patients (ORR 82%). Amongst the responders, 10 patients had PIT (ORR for PIT of 59%) versus 30 patients had SFPR (ORR for SFPR of 94%). TPO-RAs have an overall favorable response rate for both PIT and SFPR with a reasonable safety profile. However, given the lack of control groups, study heterogeneity, and the potential publication bias, the results should be interpreted with caution.